HOME >> BIOLOGY >> NEWS
Extra-aggressive form of idiopathic pulmonary fibrosis identified

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disorder from which most patients die within 5 years after diagnosis. The disease is characterized by the insidious onset of dyspnea or cough and usually evolves slowly.

Now, Selman and coworkers present in an article published in the online, open-access journal PLoS ONE on Wednesday 30th May, strong evidence indicating that a subset of IPF patients has a short duration of symptoms before diagnosis and display an accelerated clinical course to end-stage disease. The authors postulate that these "rapid progressor" patients, predominantly smoking males, represent a distinct clinical phenotype compared with the usual "slow progressors" patients.

"These findings highlight the variability in the progression and outcome of IPF, and may explain, in part, the difficulty in obtaining significant and reproducible results in studies of therapeutic interventions in patients with IPF," said Dr Selman, who is the Director of Research at the National Institute of Respiratory Research in Mexico City and the lead author on this publication. "They also suggest that physicians should pay more attention to the time of onset of symptoms, and to look for other signs that allow the identification of these rapid progressor patients".

In this study the authors performed global gene expression analysis and other molecular studies in a subset of patients and identified a number of genes that were differentially expressed in both groups, suggesting that rapid progressors are biologically distinct from slow progressors.

"While preliminary, these results may allow investigators to identify biomarkers of disease progression," said Dr King, who is the Chief of Medicine at San Francisco General Hospital and an internationally renowned expert in research and management of pulmonary fibrosis.

The senior author on this paper, Dr Naftali Kaminski, who is the Director
'"/>

Contact: Moiss Selman
mselmanl@yahoo.com.mx
Public Library of Science
29-May-2007


Page: 1 2

Related biology news :

1. Gene expression patterns predict rapid decline in idiopathic pulmonary fibrosis patients
2. A candidate gene for familial idiopathic pulmonary fibrosis identified
3. New approach to pulmonary hypertension shows promise
4. Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness
5. NIH gives PITT $13 million grant for chronic obstructive pulmonary disease research
6. Scientific meeting on pulmonary hypertension, December 7-8
7. Leveling the field for babies with persistent pulmonary hypertension
8. U-M scientists target key cells and signals that trigger pulmonary fibrosis
9. First different black/white mechanism in pulmonary fibrosis/scleroderma identified
10. Against pulmonary fibrosis
11. First report of cancer drug Gleevec as new target therapy for pulmonary hypertension

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/5/2016)... , Feb. 5, 2016 ... addition of the "Global Facial Recognition ... --> http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced ... Recognition Market 2016-2020" report to their ... ( http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the addition ...
(Date:2/3/2016)... , February 3, 2016 ... market research report "Automated Fingerprint Identification System Market by ... Search), Application (Banking & Finance, Government, Healthcare, and Transportation) ... MarketsandMarkets, the market is expected to be worth USD ... 21.0% between 2015 and 2020. The transformation and technology ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 ... healthcare facilities are primarily focused on medical ... that measure point-of-care parameters. Wearable devices that ... a user,s freedom of movement are being ... sensors for human biomedical signal acquisition coupled ...
Breaking Biology News(10 mins):
(Date:2/11/2016)... February 11, 2016 ... or "Company") (OTCQB: PSID), a life sciences company ... its Thermomedics subsidiary, which markets the Caregiver® FDA-cleared ... plan in January 2016, including entering into agreements ... monthly sales growth, and establishing several near-term pipeline ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... of its new stem cell treatment clinic in Quito, Ecuador. The new facility ... and trauma applications to patients from around the world. , The new ...
(Date:2/10/2016)... Feb. 10, 2016 NX Prenatal Inc., a ... NeXosome® technology for early warning of adverse pregnancy ... recent study by Dr. Thomas McElrath ... Maternal Fetal Medicine,s (SMFM) annual meeting held in ... , 2016.  The presentation reported initial positive top-line ...
(Date:2/10/2016)...  Allergan plc (NYSE: AGN ) a leading ... , Allergan,s CEO and President, will be featured as ... the RBC Capital Markets Healthcare Conference on Tuesday, February ... York Palace Hotel in New York, NY ... can be accessed on Allergan,s Investor Relations web site ...
Breaking Biology Technology:
Cached News: